Michael P. Bailey
Michael P. Bailey: Chairman of the Board, Independent
Michael has more than 25 years of experience in the pharmaceutical industry, where he has been instrumental in the commercial planning and launch of several new medicines across multiple oncology indications.
He currently is Chief Executive Officer and Board member of AVEO Oncology which he joined in 2010 as Chief Commercial Officer, subsequently serving Chief Business Officer and then Chief Executive Officer.
He previously held a variety of leadership roles in commercial operations, sales, business development, and strategic planning across numerous biotech and pharmaceutical companies, including ImClone Systems (now Eli Lilly), Genentech, Synta Pharmaceuticals, and Smithkline Beecham. Michael holds an M.B.A. in International Marketing from the Mendoza College of Business at University of Notre Dame and a B.S. in Psychology from St. Lawrence University.
Andrew Hall, B. Med. Sci., M.Sc.
Chief Executive Officer
Andrew brings more than 20 years of executive experience in biopharmaceuticals and life science. He has spent his career focused on corporate and portfolio strategy, as well as business development and commercial operations with industry leaders such as Celgene, Merck, Schering-Plough and Bristol-Meyers Squibb spearheading new product development, analytics and commercial strategy for immunology & inflammation, oncology, women's health, cardiovascular portfolios and more. In his most recent roles with Celgene, Andrew had led new product analytics and commercial strategy for the Inflammation & Immunology division and led new critical alliances across all therapeutic areas. Andrew Hall holds a Master of Science from RMIT University and a Bachelor of Medical Science with Honors from Melbourne University.
Julia P. Gregory
Director, Independent - Member of the Compensation Committee
Julia P. Gregory is a seasoned biotechnology executive with a proven track record for successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues and has extensive experience in recruiting outstanding management teams. As a biotechnology executive, she has raised more than $1.5 billion for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche) and Human Genome Sciences (now GSK). Most recently, she was CEO and Board member of ContraFect (NASDAQ: CFRX), which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO and Board member of FivePrime Therapeutics (NASDAQ: FXRX), which discovered and developed innovative protein and antibody therapeutics in the fields of oncology and immunology. She was the EVP Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) during its $220 million initial public offering and was involved in the creation of Lexicon’s $500 million private equity investment plan. In addition to her deep experience in the biopharmaceutical industry, Ms. Gregory has twenty years of investment banking experience, starting at Dillon, Read & Co., Inc. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory has also served on the Board of Directors at The Global TB Alliance for Drug Development, Clinipace Worldwide, and the Institute for the Study of Aging, a private foundation for Alzheimers. She is currently a Director at Iconic Therapeutics, the Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN). Ms. Gregory attained a Masters of Business Administration from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa.
Michael Kalos, PhD
Director, Independent - Member Compensation Committee
Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy, and brings over 25 years of experience and expertise in cell therapy, oncology vaccines, and immune-oncology. Prior to his career in the biopharmaceutical sector, Dr. Kalos spent 10 years in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs. The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the clinical cell therapy program at Penn, including development of the CTL019 program, which was licensed to Novartis and led to Kymriah, the first approved CART cell therapy product. Dr. Kalos obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center. He has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy. He also has over 26 issued patents in the fields of cell therapy, immunotherapy, and vaccines. Dr. Kalos now actively serves in an advisory capacity for a number of biopharmaceutical companies as well as international immunotherapy consortia and organizations.
Director, Independent – Chairman of the Audit Committee
Kyle Kuvalanka brings over 20 years of experience as a senior leader in the biopharmaceutical industry. Currently, Mr. Kuvalanka serves as Chief Financial Officer and Chief Operating Officer at Goldfinch Bio, a kidney precision medicines company. Prior to joining Goldfinch Bio, Mr. Kuvalanka advised private biopharmaceutical and portfolio companies of venture capital firms, including Third Rock Ventures, on their corporate and financial strategies and helped to build several investor syndicates. Previously, he served as Chief Operating Officer and Principal Financial and Accounting Officer at Syros Pharmaceuticals (Nasdaq: SYRS) and Chief Business Officer and Principal Financial and Accounting Officer at Blueprint Medicines (Nasdaq; BPMC). In these roles, Mr. Kuvalanka helped to transition the companies from early-stage start-ups to publicly traded, clinical-stage organizations. In particular, he built the business and finance functions, led the execution of several financings, including the companies’ initial public offerings, and led the negotiations of the companies’ early strategic collaborations. Earlier in his career, Mr. Kuvalanka worked in roles of increasing responsibility over twelve years at Millennium: The Takeda Oncology Company, including as Vice President of Business Development and Corporate Strategy. He holds an MBA from the Wharton School of the University of Pennsylvania, and a BA with Honors from Wesleyan University.
Saman Maleki, PhD
Director, Independent - Member of the Governance Committee
Dr. Maleki is a Translational Immuno-Oncology Scientist with an extensive training background in Immunology, Cancer Biology, and Microbiology. Dr. Maleki also has extensive experience with clinical research in cancer immunotherapy and oncology. Dr. Maleki has pioneered phase I clinical trials in Canada that combine fecal microbiota transplant (FMT) plus immunotherapy in melanoma, renal cell carcinoma, non-small cell lung cancer, and pancreatic cancer patients.
Dr. Maleki is an Assistant Professor in the Departments of Oncology, Pathology and Laboratory Medicine, and Medical Biophysics at Western University. He is also a Translational Immuno-Oncology Scientist at Lawson Health Research Institute and a scientist at the Ontario Institute of Cancer Research (OICR).
Dr. Maleki’s academic research focuses on sensitizing hard-to-treat cancers to immunotherapy via tumor vaccine strategies targeting DNA repair pathways in cancer cells or modifying the gut microbiome in the host. As a tumor immunologist, Dr. Maleki is tumor agnostic and brings many years of experience working on various cancers, including neuroblastoma (childhood cancer), melanoma, lung cancer, kidney cancer, prostate cancer, pancreatic cancer, and head and neck cancer, to IMV.
Dr. Maleki regularly collaborates with biotech companies in the Immuno-Oncology space and has helped move oncology and Immuno-Oncology drug candidates from pre-clinical to phase I clinical trials in patients. In addition, as an advocate of better academia and industry collaborations, Dr. Maleki is involved with several professional societies that aim to increase collaboration between academia and industry and facilitate continuous training and education for scientists and clinicians involved in immunotherapy research and clinical use in both sectors.
Shermaine Tilley, PhD
Director, Independent - Chairman of the Compensation Committee and Member of the Governance Committee
Shermaine is a Managing Partner at CTI Life Sciences Fund (CTI LSF), a Montreal-based venture capital fund investing across Canada as well as in the United States. CTI LSF currently has $245M under management, comprised of 2014 vintage Fund II that is open for investment as well as a 2006 vintage Fund I. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago–acquired by Mitsubishi Tanabe in 2013–as well as those in Phemi, Xagenic and Zymeworks. She was also a board observer in Enobia that was acquired by Alexion in 2012 in the largest takeout of a private development-stage biotech for $1.1B, assuming all milestones are received. Prior to joining CTI LSF in 2006, Shermain was Senior Vice President at Drug Royalty Corporation, the world’s first private equity firm doing royalty transactions in the biotech/pharma space. At DRC (now DRI), she played a leading role in closing 12 transactions totaling over $200M in investments. Before DRC, Shermaine managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious disease for 10 years. Shermaine holds a PhD in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto and is a member of the CFA Society of Toronto. She currently sits on the boards of Phemi, Xagenic, Zymeworks and BIOTECanada.
Markus Warmuth, MD
Director, Independent - Member Audit and Governance Committees
As a long-time advocate for industry collaboration and data-driven drug discovery, Markus brings over 20 years of immuno-oncology and precision medicine drug development expertise to IMV. He currently serves as a Venture Partner at Versant Ventures and Chief Executive Officer of Monte Rosa Therapeutics. He had joined Versant from Third Rock Ventures, where he worked as an EIR and played an integral role in the venture capital firm’s formation of new biotech companies. Prior to his role at Third Rock, Markus spent seven years as the Chief Executive Officer of H3 Biomedicine, a biopharmaceutical company that specializes in the discovery and development of genomics-based precision oncology treatments. Markus has also previously served in multiple roles at the Novartis Institute for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. He earned his MD from Ludwig Maximilian University, in Munich, Germany. He currently resides with his family in Boston, MA.